CTNNB1 and prostate cancer: Specifically, half of the “prostate cancer” pathway DEGsSD had previously been referred to in the literature (AR, CDKN1A, CTNNB1, EGFR, KLK2, NKX3-1, PDGFRA, SRD5A2) (Figure 4B, Table S1).